IDEAYA Biosciences, Inc. (IDYA) Spending and interest coverage
- R&D / revenue · 12 months: Value 159.75%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 23.58%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 159.75% | Research and development expense / revenue. Period ending 2026-06-30. $374.01M ÷ $234.13M × 100 ≈ 159.75% |
| Stock-based compensation / revenue · 12 months | 23.58% | Share-based compensation / revenue. Period ending 2026-06-30. $55.20M ÷ $234.13M × 100 ≈ 23.58% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 374.01M USD | Research and Development Expense |
| Revenue | 234.13M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 55.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -216.95M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $374.01M | $234.13M | $55.20M | $-216.95M | (m) | 159.75% | 23.58% | (m) | (m) |
| 2026-03-31 | $339.54M | (m) | $50.41M | $-183.47M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $314.70M | $218.71M | $46.12M | $-159.31M | (m) | 143.89% | 21.08% | (m) | (m) |
| 2025-09-30 | $368.29M | $214.83M | $43.81M | $-208.88M | (m) | 171.43% | 20.39% | (m) | (m) |
| 2025-06-30 | $342.45M | (m) | $40.80M | $-384.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $322.75M | (m) | $38.67M | $-360.35M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $294.67M | $7.00M | $34.75M | $-326.98M | (m) | 4209.61% | 496.37% | (m) | (m) |
| 2024-09-30 | $193.26M | $3.92M | $30.06M | $-224.75M | (m) | 4927.59% | 766.42% | (m) | (m) |
| 2024-06-30 | $169.81M | $11.96M | $26.14M | $-191.38M | (m) | 1419.69% | 218.59% | (m) | (m) |
| 2024-03-31 | $144.45M | $15.51M | $21.14M | $-159.17M | (m) | 931.66% | 136.36% | (m) | (m) |
| 2023-12-31 | $129.51M | $23.39M | $18.49M | $-134.43M | (m) | 553.81% | 79.06% | (m) | (m) |
| 2023-09-30 | $115.45M | $23.48M | $16.67M | $-118.95M | (m) | 491.59% | 70.96% | (m) | (m) |
| 2023-06-30 | $104.12M | $45.15M | $14.37M | $-84.77M | (m) | 230.64% | 31.83% | (m) | (m) |
| 2023-03-31 | $97.74M | $47.45M | $12.68M | $-74.56M | (m) | 205.97% | 26.73% | (m) | (m) |
| 2022-12-31 | $89.54M | $50.93M | $11.63M | $-62.50M | (m) | 175.80% | 22.83% | (m) | (m) |
| 2022-09-30 | $80.93M | $49.87M | $10.72M | $-54.43M | (m) | 162.28% | 21.49% | (m) | (m) |
| 2022-06-30 | $74.06M | $29.15M | $9.91M | $-66.80M | (m) | 254.09% | 34.00% | (m) | (m) |
| 2022-03-31 | $66.25M | $32.05M | $8.92M | $-55.35M | (m) | 206.68% | 27.84% | (m) | (m) |
| 2021-12-31 | $58.16M | $27.94M | $8.24M | $-50.27M | (m) | 208.15% | 29.48% | (m) | (m) |
| 2021-09-30 | $54.10M | $35.55M | $7.22M | $-37.18M | (m) | 152.18% | 20.31% | (m) | (m) |
| 2021-06-30 | $48.62M | $35.54M | $6.00M | $-30.46M | (m) | 136.81% | 16.89% | (m) | (m) |
| 2021-03-31 | $42.24M | (m) | $4.77M | $-32.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $39.70M | $19.54M | $3.61M | $-35.34M | (m) | 203.18% | 18.47% | (m) | (m) |
| 2020-09-30 | $36.19M | (m) | $3.28M | $-41.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $35.09M | (m) | $2.82M | $-48.01M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $35.35M | (m) | $2.54M | $-46.66M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $34.32M | (m) | $2.17M | $-44.27M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $31.75M | (m) | $950.00K | $-36.42M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $12.38M | (m) | $136.00K | $-14.44M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |